Figure 2From: Immunogenicity of idursulfase and clinical outcomes in very young patients (16 months to 7.5 years) with mucopolysaccharidosis II (Hunter syndrome)Kaplan-Meier plot of time to the first IRAE after the landmark point for patients with no IRAEs prior to the landmark point, by PAb status at the Study Week 9 visit. IRAE, infusion-related adverse event; PAb+, persistently antibody positive; PAb−, persistently antibody negative.Back to article page